Renovascular safety of antiangiogenics

Trial Profile

Renovascular safety of antiangiogenics

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Sunitinib (Primary)
  • Indications Breast cancer; Prostate cancer
  • Focus Adverse reactions
  • Acronyms MARS
  • Most Recent Events

    • 02 Jun 2015 Results in patients with prostate cancer receiving sunitinib presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 19 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top